


FIG. 1


APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 2A




APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 2B




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 2C



APPROVED	O. G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

FIG. 3A



APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 3B



APPROVED	O. G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS





FIG. 3C

APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 4A



APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

B

Protein Tyrosine Kinase	Residue at Region A	Residue at Region B	Residue at Region C	Residue at Region D	Residue at Region E	Residue at Region F
JAK3	Pro906	Tyr904	Leu905	Met902	Ala966	Asp912
JAK2	Pro933	Tyr931	Leu932	Met929	Gly993	Asp939
JAK1	Pro948	Phe946	Leu947	Met944	Gly1008	Glu954
BTK	Ala478	Tyr476	Met477	Thr474	Ser538	Asn484
SYK	Glu342	Met340	Ala341	Met338	Ser403	Lys348
HCK	Ala342	Phe340	Met341	Ala342	Ala403	Asp348
LYN	Ala323	Tyr321	Met322	Ala323	Ala384	Asp329
IRK	Ala1080	Leu1078	Met1079	Met1076	Gly1149	Ser1086

FIG. 4B

FIG. 5A




FIG. 5B




FIG. 5C






FIG. 5D



APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 5E



APPROVED		
By	CLASS	SUB CLASS
DRAFTSMAN		

FIG. 6A





FIG. 6B



APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 6C





FIG. 6D



APPROVED	O G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 7A




FIG. 7B




FIG. 7C

APPROVED	O.S. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 7D1

D.1 Con



FIG. 7D2

D.2 WHI-P131



APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 8A

APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 8B1






FIG. 8B2



APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 9B



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 10

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 11

APPROVED:	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 12

APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


FIG. 13A



FIG. 13B



FIG. 13C



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 14

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 15

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 16

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		





FIG. 17


APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 18C



C. DDE9501+UVB

FIG. 18B



B. UVB

FIG. 18A



A. Control

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


FIG. 19C



FIG. 19B



FIG. 19A



APPROVED	O. E. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

FIG. 20A





FIG. 20B



FIG. 20C



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 21A

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 21B

APPROVED	O. G. F. G.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 21C

APPROVED	10	1
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 22

APPROVED	O. G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS




FIG. 23

APPROVED	O G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 24

APPROVED	O. G. F. G.
BY	CLASS
DRAFTSMAN	SUBCLASS




FIG. 25

WHI-P131 (60 mg/kg/day) - effects on GVHD development

Cumulative proportion surviving

<u>Group</u>	<u>n</u>	<u>Cumulative proportion surviving</u>			median survival (d)	Logrank	
		<u>30</u>	<u>60</u>	<u>90</u>		<u>p value</u>	<u>vs.</u>
CONTROL	51	90.2 ± 4.2	17.6 ± 5.3	2.0 ± 1.9	44		Control WHI-P131
WHI-P131	9	100 ± 0	77.8 ± 13.9	33.3 ± 15.7	82	0.0003	
WHI-P132	9	88.9 ± 10.5	11.1 ± 10.5	0 ± 0	44	0.485	
Methotrexate	16	93.8 ± 6.1	56.2 ± 12.4	25.0 ± 10.8	63.5	0.0009	0.356
Methotrexate + WHI-P131	13	100 ± 0	76.9 ± 11.7	61.5 ± 13.5	87	<0.0001	0.320
Cyclosporine A	15	73.3 ± 11.4	26.7 ± 11.4	13.3 ± 8.8	45	0.493	0.029
Cyclosporine A + WHI-P131	15	80.0 ± 10.3	33.3 ± 12.2	20.0 ± 10.3	51	0.198	0.067

Methotrexate vs.
Methotrexate + WHI-P131
0.062

FIG. 26

APPROVED	O. G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 27

APPROVED	O. G. FIG.
BY	CLASS SUBCLASS




FIG. 28




FIG. 29

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 30

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 31

APPROVED	O. G. FIG.
By	CLASS SUBCLASS
DATE	




FIG. 32

APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS




FIG. 33




FIG. 34

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 35

APPROVED	O.S. FIG.
BY	CLASS SUBCLASS
DATE	




FIG. 36




FIG. 37

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 38




FIG. 39

APPROVED	O.S.F.G.
BY	CLASS SUBCLASS
DRAFTSMAN	




FIG. 40




FIG. 41




FIG. 42